These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 32171601)

  • 21. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A; Larsson K; Welén K; Damber JE
    Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer.
    Fukuoka K; Teishima J; Nagamatsu H; Inoue S; Hayashi T; Mita K; Shigeta M; Kobayashi K; Kajiwara M; Kadonishi Y; Tacho T; Matsubara A
    Int Urol Nephrol; 2020 Jan; 52(1):77-85. PubMed ID: 31552574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Han KS; Hong SJ
    Yonsei Med J; 2015 Mar; 56(2):368-74. PubMed ID: 25683983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
    Schweizer MT; Haugk K; McKiernan JS; Gulati R; Cheng HH; Maes JL; Dumpit RF; Nelson PS; Montgomery B; McCune JS; Plymate SR; Yu EY
    PLoS One; 2018; 13(6):e0198389. PubMed ID: 29856824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients.
    Lo EN; Beckett LA; Pan CX; Robles D; Suga JM; Sands JM; Lara PN
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):144-8. PubMed ID: 25667107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma.
    Bland LB; Garzotto M; DeLoughery TG; Ryan CW; Schuff KG; Wersinger EM; Lemmon D; Beer TM
    Cancer; 2005 Feb; 103(4):717-23. PubMed ID: 15641029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
    Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H
    Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
    Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
    BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer.
    Roviello G; Zanotti L; Gobbi A; Dester M; Generali D; Pacifico C; Cappelletti MR; Bonetta A
    Clin Genitourin Cancer; 2017 Jun; 15(3):371-375. PubMed ID: 27692697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
    de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
    BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer.
    Yu EY; Hancock ML; Aronson W; Flaig T; Belkoff L; Tutrone R; Taylor R; Hardigan PC; Getzenberg RH
    Clin Genitourin Cancer; 2020 Dec; 18(6):436-443. PubMed ID: 32321673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer.
    Kodama H; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Narita T; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
    Clin Genitourin Cancer; 2019 Dec; 17(6):e1091-e1098. PubMed ID: 31575477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer.
    Jung J; Lee C; Lee C; Kwon T; You D; Jeong IG; Hong JH; Ahn H; Kim CS
    Korean J Urol; 2015 Sep; 56(9):630-6. PubMed ID: 26366275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent Androgen and Estrogen Ablation and Inhibition of Steroid Biosynthetic Enzyme Treatment for Castration-resistant Prostate Cancer.
    Sinha AA; Pomroy FE; Wilson MJ
    Anticancer Res; 2016 Aug; 36(8):3847-54. PubMed ID: 27466486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
    Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
    BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.